Synergy Pharmaceuticals Announces Data Presentations on Plecanatide and SP-333 at Two Scientific Meetings
10/3/2013 7:14:55 AM
Synergy Pharmaceuticals Inc. (Nasdaq:SGYP) today announced presentations on plecanatide and SP-333, its proprietary guanylate cyclase-C (GC-C) agonists in development for gastrointestinal (GI) disorders, will take place at two scientific meetings this month.
Plecanatide, Synergy’s lead GC-C agonist for chronic idiopathic constipation and irritable bowel syndrome with constipation, will be featured in two oral presentations at the United European Gastroenterology (UEG) Week being held October 12-16 in Berlin, Germany.
Help employers find you! Check out all the jobs and post your resume.
comments powered by